Objectives: Meloxicam therapy may benefit cats with degenerative joint disease, and retrospective studies suggest it could slow kidney disease progression and increase survival. This study aimed to prospectively evaluate the renal effects of low-dose meloxicam treatment (0.02 mg/kg/day) over 6 months in cats with chronic kidney disease (CKD).
Methods: Twenty-one cats with stable International Renal Interest Society stage 2 or 3 CKD were recruited and randomized to placebo or meloxicam groups. Cats were evaluated at baseline and at 1, 3 and 6 months, including blood pressure, chemistry, symmetric dimethylarginine (SDMA), glomerular filtration rate (GFR), urinalysis, urine protein:creatinine ratio (UPC), urine transforming growth factor-beta (β):creatinine ratio, urine clusterin, urine cystatin B and serum inosine.
Results: No statistical difference was observed in systolic blood pressure, blood urea nitrogen, creatinine, SDMA, GFR, urine transforming growth factor-β:creatinine ratio, urine clusterin, urine cystatin B or serum inosine in cats receiving meloxicam vs placebo. Mean UPC was greater in the meloxicam group (0.33) than the placebo group (0.1) at 6 months ( = 0.006). Four cats had meloxicam discontinued owing to potential (mainly gastrointestinal) adverse effects.
Conclusions And Relevance: No decline in renal excretory function was observed when meloxicam was administered to cats with CKD. However, gastrointestinal adverse effects were observed, and cats that received meloxicam had greater proteinuria at 6 months than cats that received placebo. As proteinuria is associated with negative outcomes (progression of azotemia and hypertension) in cats with CKD, this finding suggests that meloxicam should be used with caution in cats with CKD and UPC monitored. Until further research is available, clinicians should weigh the risk of potential increased proteinuria against quality of life benefits when considering meloxicam for analgesia in cats with renal disease.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10741344 | PMC |
| http://dx.doi.org/10.1177/1098612X20935750 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Transcriptomic and genetic profiling in a spontaneous non-human primate model of hypertrophic cardiomyopathy and sudden cardiac death.
Sci Rep
December 2024
Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, 1060 William Moore Dr, Raleigh, NC, 27607, USA.
Hypertrophic cardiomyopathy (HCM) afflicts humans, cats, pigs, and rhesus macaques. Disease sequelae include congestive heart failure, thromboembolism, and sudden cardiac death (SCD). Sarcomeric mutations explain some human and cat cases, however, the molecular basis in rhesus macaques remains unknown.
View Article and Find Full Text PDFFish Gastroenterology.
Vet Clin North Am Exot Anim Pract
December 2024
Zoological Medicine, Department of Clinical Sciences, Faculté de Médecine Vétérinaire, Université de Montréal, St Hyacinthe, Canada. Electronic address:
Fish represent the most common companion exotic animal in the United States and Canada in number of individuals and hold the third place after dogs and cats in terms of the number of households. Beyond companion animals, fish gastrointestinal diseases are particularly relevant for the aquaculture industry as feeding represents about 50% to 70% of the costs associated with fish production. Thus, nutrient malabsorption may have dramatic consequences both for the fish health and body condition score, but also for farmers.
View Article and Find Full Text PDFMinimally Invasive Placement of Cannulated Headless Compression Screws for Reduction of Sacroiliac Luxation in 14 Cats.
Vet Comp Orthop Traumatol
December 2024
Surgery Department, Evidensia Dierenziekenhuis Hart van Brabant, Waalwijk, Brabant, The Netherlands.
Objective: To describe percutaneous fluoroscopy-guided placement of self-drilling, self-tapping, 3.0 mm cannulated headless compression screws (HCS) for surgical reduction of sacroiliac luxation (SIL) in cats, and to document clinical outcome.
Materials And Methods: Medical records of cats with SIL, managed by percutaneous fluoroscopy-guided placement of a 3.
A highly prevalent and specific cryptic plasmid pBI143 for human fecal pollution tracking in a subtropical urban river.
Water Res
December 2024
CSIRO Environment, Ecosciences Precinct, 41 Boggo Road, Dutton Park, QLD 4102, Australia. Electronic address:
Microbial source tracking (MST) is a critical tool for identifying sources of human and animal fecal pollution in aquatic environments. To enhance human fecal pollution tracking, this study evaluated the performance characteristics of pBI143, a cryptic plasmid recently identified for potential MST applications. Nucleic acid samples from ten animal species were screened for pBI143, revealing its presence in a small number of pigs, cows, dogs, cats, and flying fox fecal samples.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!